Atrioventricular nodal reentry tachycardia treatment using CARTO 3 V7 activation mapping: a new era of slow pathway radiofrequency ablation is under coming.

Autor:	Chieffo E; Department of Cardiology, ASST Ospedale Maggiore, Crema, Italy., D'Amore S; Department of Cardiology, ASST Ospedale Maggiore, Crema, Italy., De Regibus V; Department of Cardiology, ASST Ospedale Maggiore, Crema, Italy., Dossena C; Department of Cardiology, ASST Ospedale Maggiore, Crema, Italy., Frigerio L; Department of Cardiology, ASST Ospedale Maggiore, Crema, Italy., Taravelli E; Department of Cardiology, S. Croce e Carle Hospital, Cuneo, Italy., Ferrazzano C; Biosense Webster, Johnson & Johnson Medical S.p.A., Pomezia, Italy., De Iuliis P; Biosense Webster, Johnson & Johnson Medical S.p.A., Pomezia, Italy., Cacucci M; Department of Cardiology, ASST Ospedale Maggiore, Crema, Italy., Landolina ME; Department of Cardiology, ASST Ospedale Maggiore, Crema, Italy.
Jazyk:	angličtina
Zdroj:	Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2023 Sep 29; Vol. 10, pp. 1144988. Date of Electronic Publication: 2023 Sep 29 (Print Publication: 2023).
DOI:	10.3389/fcvm.2023.1144988
Abstrakt:	Background: Slow pathway (SP) ablation is the cornerstone for atrioventricular nodal reentry tachycardia (AVNRT) treatment, and a low-voltage bridge offers a good target during mapping using low x-ray exposure. We aimed to assess a new tool to identify SP by activation mapping using the last CARTO3® version, i.e., CARTO PRIME® V7 (Biosense Webster, Diamond Bar, CA, USA). Methods and Results: Right atrial septum and triangle of Koch 3D-activation map were obtained from intracardiac contact mapping during low x-ray CARTO 3® procedure. In 60 patients (mean age 60.3 ± 14.7, 61% females) undergoing ablation for AVNRT, an automatic activation map using a DECANAV® mapping catheter and CARTO® Confidense™, Coherent, and FAM DX software modules were obtained. The SP was identified in all patients as the latest atrioventricular node activation area; RF catheter ablation (RFCA) in that region elicited junctional beats. The mean procedural time was 150.3 ± 48.3 min, the mean fluoroscopy time exposure was 2.9 ± 2 min, the mean dose-area product (DAP) was 16.5 ± 2.7 cGy/cm 2 . The mean number of RF applications was 3.9 ± 2, the mean ablation index was 428.6 ± 96.6, and the mean contact force was 8 ± 2.8 g. There were no adverse event during the procedure, and no AVNRT recurrences occurred during a mean follow-up of 14.3 ± 8.3 months. Conclusion: Ablation of the SP by automatic mapping using Confidense™, Coherent, and FAM DX software modules is an innovative, safe, and effective approach to AVNRT ablation. The CARTO3® V7 system shows on a 3D map the latest AV node activation area during sinus rhythm allowing low fluoroscopy time and highly effective RFCA. Competing Interests: ML is a member of speaker bureau of Medtronic and Boston Scientific. CF and PD are employed by Biosense Webster Corporation, a Johnson and Johnson Company. CF and PD did not have access to study results. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer GM declared a past co-authorship with the author ML to the handling editor. (© 2023 Chieffo, D’Amore, De Regibus, Dossena, Frigerio, Taravelli, Ferrazzano, De Iuliis, Cacucci and Landolina.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu